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Tumor angiogenesis is an essential process for supplying rapidly growing malignant
tissues with essential nutrients and oxygen. An angiogenic switch allows tumor cells
to survive and grow, and provides them access to vasculature resulting in metastatic
disease. Monocyte-derived macrophages recruited and reprogrammed by tumor cells
serve as a major source of angiogenic factors boosting the angiogenic switch. Tumor
endothelium releases angiopoietin-2 and further facilitates recruitment of TIE2 receptor
expressing monocytes (TEM) into tumor sites. Tumor-associated macrophages (TAM)
sense hypoxia in avascular areas of tumors, and react by production of angiogenic factors
such as VEGFA. VEGFA stimulates chemotaxis of endothelial cells (EC) and macrophages.
In some tumors, TAM appeared to be a major source of MMP9. Elevated expression
of MMP9 by TAM mediates extracellular matrix (ECM) degradation and the release of
bioactive VEGFA. Other angiogenic factors released by TAM include basic fibroblast
growth factor (bFGF), thymidine phosphorylase (TP), urokinase-type plasminogen activator
(uPA), and adrenomedullin (ADM). The same factors used by macrophages for the
induction of angiogenesis [like vascular endothelial growth factor A (VEGF-A) and MMP9]
support lymphangiogenesis. TAM can express LYVE-1, one of the established markers
of lymphatic endothelium. TAM support tumor lymphangiogenesis not only by secretion
of pro-lymphangiogenic factors but also by trans-differentiation into lymphatic EC. New
pro-angiogenic factor YKL-40 belongs to a family of mammalian chitinase-like proteins
(CLP) that act as cytokines or growth factors. Human CLP family comprises YKL-40,
YKL-39, and SI-CLP. Production of all three CLP in macrophages is antagonistically
regulated by cytokines. It was recently established that YKL-40 induces angiogenesis
in vitro and in animal tumor models. YKL-40-neutralizing monoclonal antibody blocks tumor
angiogenesis and progression. The role of YKL-39 and SI-CLP in tumor angiogenesis and
lymphangiogenesis remains to be investigated.
Keywords: tumor-associated macrophages, TIE2 receptor, VEGF, LYVE-1, stabilin-1, chitinase-like protein
INTRODUCTION
Tumor-associated macrophages (TAM) are key cells controlling
tumor angiogenesis. TAM originate from circulating monocytes
which are recruited to the tumor site and programmed by tumor-
derived factors such as colony-stimulating factor-1 (CSF-1), vas-
cular endothelial growth factor A (VEGF-A) and CC chemokine
ligand 2 (CCL2) (Mantovani et al., 1992; Qian and Pollard, 2010).
These and other factors in the tumor microenvironment shape
the TAM phenotype and skew them toward tumor-supportive
M2-polarized macrophages, although M1-polarized TAM with
anti-tumor activity were also reported in several types of can-
cer (Forssell et al., 2007; Galarneau et al., 2007; Ong et al., 2012;
Sica and Mantovani, 2012). Macrophage density correlates with
poor prognosis in many types of human cancer. Tumor sup-
porting functions of TAM including stimulation of tumor cell
growth and the creation of favorable conditions for tumor cell
intravasation into vessels andmetastatic spread are well-described
in animal models of breast cancer (Lin et al., 2006; Qian and
Pollard, 2010). Numerous recent studies have demonstrated that
TAM function as major producers of pro-angiogenic factors in
malignant tumors. The angiogenic switch is an important step in
cancer progression. The formation of new blood vessels is essen-
tial for fast growing tumor cells to be supplied with nutrients
and oxygen. The angiogenic switch allows tumor cells to survive
and provides them access to vasculature, which may result in the
escape of malignant cells into circulation and onset of metastatic
disease.Macrophages recruited and reprogrammed by tumor cells
produce factors mediating the angiogenic switch (Huang et al.,
2002; Lin et al., 2006; Du et al., 2008). The contribution of TAM
to tumor angiogenesis was described in animal models of breast
cancer, melanoma, prostate cancer, cervical cancer, and ovarian
cancer (Huang et al., 2002; Egami et al., 2003; Giraudo et al., 2004;
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Lin et al., 2006; Halin et al., 2009). A positive correlation between
TAM infiltration and angiogenesis was found in many human
cancers including breast cancer, melanoma, pulmonary adenocar-
cinoma, glioma, gastric cancer, B-cell non-Hodgkin’s lymphoma,
mucoepidermoid carcinoma of salivary glands, and leiomyosar-
coma (Leek et al., 1996; Nishie et al., 1999; Takanami et al., 1999;
Vacca et al., 1999; Torisu et al., 2000; Shieh et al., 2009; Espinosa
et al., 2011; Wu et al., 2012).
Clear evidence for the role of TAM in tumor angiogenesis was
reported by Lin and colleagues using the polyoma virus mid-
dle T oncogene (MMTV-PyMT) spontaneous mouse model of
mammary adenocarcinoma (Lin et al., 2006). Increased infiltra-
tion of the primary tumor with macrophages was associated with
an angiogenic switch. In CSF-1-null mice, macrophage infiltra-
tion of the tumor site was significantly lower and accompanied
by impaired development of the vasculature network. This was a
direct effect of the absence of macrophages in the tumors since
the restoration of macrophage numbers in the tumors of CSF-
1-null mice by the transgenic expression of CSF-1, specifically
in the mammary epithelium, resulted in the increase of ves-
sel density. VEGF was depleted in the stromal cells of tumors
of CSF-1 null mice suggesting that this is a significant reason
of impaired angiogenesis. Another in vivo study demonstrated
that human breast cancer spheroids implanted into nude mice
induced more pronounced vascularization if they were infiltrated
with macrophages before implantation (Huang et al., 2002).
In this model, macrophages contributed significantly to VEGF
release by spheroids and increased the angiogenic response. Up
to date, VEGF-A is the best characterized TAM-derived cytokine
involved in tumor angiogenesis.
VEGF PRODUCTION AND PROCESSING BY TAM
The ability of TAM to accelerate vessel growth is mediated
through the up-regulation and release of several pro-angiogenic
factors. The tumor microenvironment polarizes macrophages
toward M2 or a mixed M1/M2 phenotype, which is character-
ized by elevated expression of potent pro-angiogenic factors (Ly
et al., 2010; Rolny et al., 2011). Re-polarization of the TAM
phenotype toward M1 manifests in inhibition of pro-angiogenic
activity and elevated expression of anti-angiogenic factors such
as CXC-chemokine ligand 9 (CXCL9) and IFN-β (Rolny et al.,
2011). VEGF-A is known as a major pro-angiogenic cytokine
released by TAM. Its levels correlate with TAM density in sev-
eral types of human cancer (Valkovic et al., 2002; Shieh et al.,
2009). In breast cancer, TAM produce VEGF-A in hypoxic avas-
cular areas of tumors (Lewis et al., 2000). Recently, the MHCIIlow
subset of TAM which resides in hypoxic areas of tumors was
shown to be associated with a pro-angiogenic gene signature and
increased VEGF-A expression (Laoui et al., 2013). The accumu-
lation and retention of TAM in hypoxic areas of tumors seems to
be specifically regulated by hypoxia-induced factor semaphorin
3A which triggers macrophage recruitment through VEGFR1
(Casazza et al., 2013). In macrophages, hypoxia induces expres-
sion of hypoxia inducible factor (HIF-1α and HIF-2α) transcrip-
tion factors, the major master regulators of VEGF-A expression
(Bingle et al., 2002; Burke et al., 2002; Imtiyaz et al., 2010; Staples
et al., 2011). However, recent studies reported that HIF-1α and
HIF-2α may play opposing roles in tumor angiogenesis (Eubank
et al., 2011; Roda et al., 2012). In a mouse melanoma model,
chemical stabilization of HIF-2α in TAM stimulated production
of a soluble form of the VEGF receptor (sVEGFR-1) which neu-
tralized biological activity of VEGF-A. This resulted in reduced
angiogenesis and tumor growth (Roda et al., 2012). In contrast,
HIF-1α expression in TAM was responsible for VEGF-A produc-
tion. In agreement with this study, co-culture of breast cancer
spheroids with wild type or HIF-1α knocked out macrophages
revealed an indispensable role of macrophage-expressed HIF-1α
in tumor angiogenesis (Werno et al., 2010). Besides hypoxia,
HIF-1-controlled VEGF-A expression can be induced by several
cytokines. The production of IL1β by TAM is able to induce HIF-
1α expression and VEGF-A release in tumors. It was shown that
IL1β stimulates HIF-1α production in several cancer cell lines
even under normoxic conditions (Jung et al., 2003). Another
common TAM-produced cytokine, transforming growth factor
β1 (TGFβ1), also contributes to VEGF-A expression in mouse
macrophages through HIF-1α/β- and Smad3/4-dependent mech-
anisms (Jeon et al., 2007). Alternatively, VEGF-A expression
can be induced by tumor-released CSF-1 (M-CSF), which acts
through NF-κB activation and, in combination with CCL2, pro-
motes pro-angiogenic functions of macrophages (Eubank et al.,
2003; Wyckoff et al., 2004). Moreover, irradiation stimulates
tumor cells to produce higher levels of CSF-1 resulting in the
enhanced infiltration of pro-angiogenic myeloid cells into the
tumor site (Rego et al., 2013; Xu et al., 2013). Upon secretion
from cells, VEGF-A associates with extracellular matrix (ECM)
and its soluble form can be released by enzymatic cleavage of
ECM by matrix metalloproteinases (MMPs) (Lee et al., 2005).
Several studies revealed that TAM can significantly contribute to
this process. In a mouse model of human ovarian cancer, TAM
were found to be a major source of MMP9. Furthermore, the
presence of MMP9-expressing TAM positively correlated with
tumor angiogenesis, tumor growth and VEGF-A levels (Huang
et al., 2002). Elevated expression of MMP9 by tumor-infiltrating
inflammatory cells in a mouse pancreatic cancer model mediated
the release of bioactive VEGF-A from its extracellular reservoir
(Bergers et al., 2000). In a similar study using a mouse glioblas-
toma tumor model, MMP9-producing macrophages and TIE2+
monocytes (TEM) contributed to the release of bioactive VEGF-
A from its ECM-bound form. These bone marrow-derived cells
were recruited into tumors by the HIF-1 target molecule CXC-
chemokine ligand CXCL12 (SDF-1α) released by tumor cells
(Du et al., 2008). It should be noted that targeting CXCL12
and its receptor CXCR4 in mouse glioblastoma prevented HIF-1-
mediated recruitment of pro-angiogenic TAM and TEM, reduced
vasculogenesis and abrogated tumor growth after irradiation
(Kioi et al., 2010). Interestingly, a recent study demonstrated that
in contrast to high-dose tumor irradiation, local low-dose gamma
irradiation of pancreatic carcinomas induced TAM with an anti-
tumor immunostimulatory phenotype. These TAM downregu-
lated HIF-1 expression and suppressed intratumoral VEGF-A
production resulting in the normalization of tumor vasculature.
This study emphasizes the plasticity of the TAM phenotype and
the possibility to revert their pro-angiogenic properties through
dampening of VEGF-A-dependent angiogenesis (De Palma et al.,
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2013; Klug et al., 2013). Altogether, most of the studies demon-
strate the indispensable role of TAM in the induction of tumor
angiogenesis either through the direct production of VEGF-A or
modulation of its accessibility in the tumor microenvironment.
Despite the undeniable role of VEGF in tumor angiogenesis,
several studies revealed that other molecular factors (presum-
ably HIF-1-induced factors) can significantly contribute to this
process (Kioi et al., 2010; Chen et al., 2012).
OTHER ANGIOGENIC FACTORS RELEASED OR
INTERNALIZED BY TAM
Besides VEGF, TAM release a panel of pro-angiogenic factors
which include tumor necrosis factor α (TNFα), basic fibroblast
growth factor (bFGF), thymidine phosphorylase (TP), urokinase-
type plasminogen activator (uPA), adrenomedullin (ADM), and
semaphorin 4D (Sema4D) (Hildenbrand et al., 1995; Leek et al.,
1998; Mantovani et al., 2007; Sierra et al., 2008; Chen et al.,
2011). TP stimulates the migration of endothelial cells (EC),
whereas uPA mediates ECM degradation and increases vascular
invasion (Hotchkiss et al., 2003; Piao et al., 2005; Basire et al.,
2006; Bijnsdorp et al., 2011). Macrophage-derived TP was asso-
ciated with angiogenesis and reduced survival in human glioma
and intestinal type gastric cancer (Yao et al., 2001; Kawahara
et al., 2010). Elevated expression of TP is correlated with a poor
prognosis in breast cancer and pancreatic cancer, and uPA expres-
sion is correlated with a poor prognosis in breast cancer (Takao
et al., 1998; Toi et al., 1999; Harbeck et al., 2002). Macrophage-
derived IL1α directly stimulated endothelial tube formation and
neovascularization, as well as growth of mouse prostate tumors
(Kwon et al., 2013). TAM-derived ADM was shown to induce
angiogenesis and tumor growth in a mouse model of melanoma,
and can potentially be implicated in human melanoma angio-
genesis (Chen et al., 2011). In mouse models of breast cancer,
TAM-produced Sema4Dwas found to be critical for tumor angio-
genesis, vessel maturation, and tumor growth (Sierra et al., 2008).
Sema4D induced motility of EC via the engagement of recep-
tor plexin B1. In Sema4D KO mice, interactions between EC
and pericytes (an essential process in vessel formation) were
disrupted. Another macrophage-derived pro-angiogenic factor,
prostaglandin E2 (PGE2), can be potentially involved in patholog-
ical angiogenesis induced in tumors by therapeutic interventions
which stimulate apoptosis. It was shown that apoptotic cells acti-
vated an angiogenic program in human macrophages resulting in
PGE2-mediated endothelial cell migration (Brecht et al., 2011).
Macrophages communicate with other cell types and control
tissue turnover not only by the release of various factors, but
also by their internalization and degradation. This clearance func-
tion is especially effective in alternatively activated macrophages
(M2) (Kzhyshkowska and Krusell, 2009). Thus, the clearance of
secreted protein acidic and rich in cystein (SPARC), a soluble
component of ECM that inhibits angiogenesis by the modula-
tion of expression of VEGF and MMPs (Zhang et al., 2012a),
has been demonstrated by us in human alternatively activated
macrophages (Kzhyshkowska et al., 2006a). Multifunctional scav-
enger receptor stabilin-1 is responsible for SPARC uptake and
targeting for degradation in lysosomes. We and others also found
in several tumor models that stabilin-1 is expressed by TAM
(Schledzewski et al., 2006; Werno et al., 2010; Algars et al., 2012;
David et al., 2012), leading to the hypothesis that stabilin-1-
mediated clearance of SPARC can affect tumor angiogenesis. The
clearance function of TAM as a mechanism of the regulation
of angiogenesis is underestimated at the moment and has to be
addressed experimentally.
TAM INDUCE ANGIOGENIC ACTIVITY IN TUMOR CELLS
The involvement of TAM in tumor angiogenesis is not limited
to the self-production of angiogenic factors. TAM are able to
release cytokines that indirectly contribute to tumor angiogene-
sis by the induction of a pro-angiogenic program in tumor cells.
It was demonstrated that human monocytes and macrophages
induced the production of the pro-angiogenic factors IL-8 and
VEGF frommelanoma and glioma cells during co-culture (Torisu
et al., 2000; Hong et al., 2009). Elevated expression of IL-8 dur-
ing co-culture with macrophages was also found in several lung
cancer, osteogenic sarcoma and hepatoma cell lines (Chen et al.,
2003). Up-regulation of IL-8 expression was presumably medi-
ated by TAM-derived TNFα and IL1α, which stimulated NF-κB
activity in tumor cells (Yao et al., 2005). Macrophage-derived
TNFα and IL-1α were necessary for the release of IL-8 and VEGF
from melanoma cells (Torisu et al., 2000). In vitro M2-polarized
monocyte-derived macrophages enhanced the angiogenic poten-
tial of human basal cell carcinoma cells through the induction
of cyclooxygenase-2 (COX-2) expression resulting in the elevated
release of VEGF and bFGF from tumor cells (Tjiu et al., 2009).
Thus, tumor cells and recruited TAM cooperate in the tumor
microenvironment to amplify the production of pro-angiogenic
factors resulting in an angiogenic switch (Figure 1).
TIE2 EXPRESSING MONOCYTES AS MAJOR INDUCERS OF
TUMOR ANGIOGENESIS
There is a growing set of evidence that specific subpopula-
tions of TIE2 receptor expressing monocytes (TEM) in mice
and humans significantly contribute to tumor angiogenesis
(Lewis et al., 2007; Matsubara et al., 2013). These mono-
cytes/macrophages are attracted into the tumors by endothelial
cell (EC)-derived cytokine angiopoietin-2 (ANG-2), which inter-
acts with its receptor TIE2 (Huang et al., 2011). In addition, TEM
express chemokine receptor CXCR4 and can be attracted into
tumors by CXCL12 (Welford et al., 2011). This subpopulation
of macrophages is associated with vessels and is highly angio-
genic acting in a paracrine manner (De Palma et al., 2005). It
is not known whether TIE2 expressing monocytes are recruited
into specific types of solid tumors and whether stimulation of
TIE2 expression in the conventional TAM associated with blood
vessels can result into development of TEM phenotype. Blood cir-
culating TIE2 expressing monocytes are already pre-programmed
to exert pro-angiogenic activity and express elevated levels of
MMP9, VEGF-A, COX-2, and Wnt5a (Coffelt et al., 2010). When
stimulated by EC-derived ANG-2, TEM additionally upregulate
several pro-angiogenic factors including TP and cathepsin B.
Moreover, ANG-2 induces the expression of IL-10 and CCL17
by TEM, factors which suppress T-cell proliferation and pro-
mote the expansion of regulatory T-cells providing tumor cells
with a way to escape from immune responses (Coffelt et al.,
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FIGURE 1 | Cross-talk between macrophages, tumor cells and
endothelium during tumor angiogenesis and lymphangiogenesis. Tumor
hypoxia and cytokine crosstalk between tumor cells (TC) and TAM results in
the induction of a pro-angiogenic program in both cell types followed by the
release of multiple soluble factors stimulating migration and proliferation of
vascular endothelial cells (VEC) either directly or through the mobilization of
extracellular matrix (ECM)-bound VEGF-A. In addition, TC and VEC are able to
attract specific population of TIE-2 expressing monocytes (TEM) with high
angiogenic potential. TAM and TEM-derived factors as well-induce growth of
tumor lymphatic vessels (LV). Through the production of factors such as
VEGF-A and MMP9 influencing growth of both lymphatic and vascular EC,
TAM link processes of tumor angio- and lymphangiogenesis.
2011). TEM were described to cause re-growth of subcutaneous
breast and lung carcinomas after local irradiation (Kozin et al.,
2010). In addition, they limited the efficacy of vascular-disrupting
compounds in murine mammary tumors, presumably initiating
vascular repair (Welford et al., 2011). Several studies reported
an important role of EC in the differentiation and functional
activity of TEM. The interaction of TEM with activated EC was
important for TIE2 upregulation and the establishment of a
pro-angiogenic program in TEM (Mazzieri et al., 2011). A block-
ade of EC-derived ANG-2 in mouse MMTV-PyMT mammary
cancer downregulated TIE2 expression in TEM and disrupted
their association with angiogenic blood vessels. The inhibition
of TIE2 expression by TEM resulted in reduced tumor angio-
genesis. In another study, co-culture of primary EC with bone
marrow-derived hematopoietic progenitor cells drove the differ-
entiation of pro-angiogenic TIE2 expressing macrophages, which
established tight associations with EC and supported tumor
growth. The expansion of macrophage colonies was induced
by EC-derived CSF-1 (He et al., 2012). Interestingly, expres-
sion profiles of TEM, resident monocytes and TIE2 express-
ing embryonic macrophages are related, suggesting that these
myeloid populations represent developmental stages of TEM
(Pucci et al., 2009). Recently, Medina and colleagues character-
ized a subpopulation of pro-angiogenic monocytes from human
peripheral blood which were also referred to as myeloid angio-
genic cells (MACs) (Medina et al., 2011). These cells had a
signature of M2-polarized macrophages and expressed a panel
of markers including CD163, IL-10 and macrophage scavenger
receptor-1 (MSR-1). Moreover, they expressed and released a
spectrum of pro-angiogenic factors such as IL-8, MMP9, and
VEGF. According to the gene expression profile, MACs resembled
TEM and induced endothelial tubule formation mediated mainly
through IL-8 release. The role of this monocytic subpopulation
in tumor angiogenesis was not described. However, their clear
pro-angiogenic properties and predisposition to M2 polarization
suggest a potential contribution to tumor angiogenesis once these
cells are recruited to the tumor site. A summary of the complex
regulation of angiogenesis by TAM is schematically presented on
Figure 1.
EFFECT OF TAM ON LYMPHANGIOGENESIS
In recent years, evidence has accumulated that macrophages
are not only critical regulators of angiogenesis, but also crucial
participants in lymphangiogenesis, both in inflammatory set-
tings and in tumors (Ran and Montgomery, 2012). Importantly,
macrophages may simultaneously induce both angiogenesis and
lymphangiogenesis by the production of VEGF-A and MMP9.
These cytokines which are abundantly produced by subpopula-
tions of TAM were shown to induce the development of both
blood and lymphatic vessels. Thus, TAM-derived factors can link
tumor angiogenesis and lymphangiogenesis (Scavelli et al., 2004;
Coffelt et al., 2009; Gomes et al., 2013) (see Figure 1).
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Macrophages can utilize two main pathways to stimulate
lymphangiogenesis: either by the direct secretion of prolym-
phangiogenic factors or by trans-differentiation into lymphatic
EC, actively taking part in the formation of lymphatic vessels
(Kerjaschki, 2005). TAM can express a major marker of lymphatic
vessels, LYVE-1 (lymphatic vessel endothelial hyaluronan recep-
tor (1), both in murine and human tumors (Schledzewski et al.,
2006; Zumsteg et al., 2009). It was reported that in mouse mod-
els of pancreatic insulinoma and prostate cancer F4/80+Lyve-1+
TAM directly integrated into peritumoral lymphatic vessels and
presumably lost their macrophage features upon this integration
(Zumsteg et al., 2009). Even though not all researchers agree with
the trans-differentiation hypothesis (Gordon et al., 2010), the
fact that certain macrophages secrete pro-lymphangiogenic fac-
tors in certain circumstances, such as in inflammation or tumors,
is undisputed. Below we review the pro-lymphangiogenic factors
secreted by tumor associated macrophages (TAM), as well as the
role of TAM density in evaluating tumor lymphangiogenesis.
FACTORS PRODUCED BY TAM THAT REGULATE
LYMPHANGIOGENESIS
There are a few factors produced by TAM that are responsible
for the induction of lymphangiogenesis, with VEGFR-3 and its
ligands, VEGF-C and VEFG-D, thought to have a key role in
it. Studies have shown that VEGF-C producing tumor cells sig-
nificantly increase intratumoral lymphangiogenesis together with
regional metastasis (Skobe et al., 2001a). Additionally, the inhibi-
tion of VEGFR-3 with receptor-specific antagonist antibodies was
shown to suppress tumor lymphangiogenesis as well as regional
and distant metastasis (Roberts et al., 2006). Schoppmann et al.
found that TAM expressing VEGF-C, VEGF-D, and VEGFR-
3 substantially increased tumor lymphatic microvessel density
(LVD) in cervical cancer (Schoppmann et al., 2002). In another
study, they showed that TAM expressing VEGF-C increased
tumor lymphangiogenesis and lymphovascular invasion in breast
cancer. Moreover, a positive correlation was found between
VEGF-C+ stromal cells and VEGF-C+ tumor cells (Schoppmann
et al., 2006). Similar findings were obtained in a study of Lewis
lung carcinoma cells in which M2 macrophages displayed the
ability to induce VEGF-C expression in tumor cells (Zhang et al.,
2012b). By depletion of VEGFR-3+ TAM with clodronate lipo-
somes, Yang et al. were able to obtain a considerable reduction
(>80%) in the secretion of VEGF-C and VEGF-D in the tumor
mass and also a significant reduction in LVD (Yang et al., 2011).
Recently, the critical role of VEGF-C producing TAM in lym-
phangiogenesis and tumor dissemination was found in mantle
cell lymphoma (Song et al., 2013). The description of VEGF-C
expressing TAM and their prolymphangiogenic influence can also
be found in a variety of other studies (Jeon et al., 2008; Moussai
et al., 2011; Ding et al., 2012; Werchau et al., 2012; Wu et al.,
2012).
Although VEGF-C, VEGF-D, and VEGFR-3 are mainly
regarded as prolymphangiogenic factors, there are studies sug-
gesting their role in angiogenesis. The mature forms of VEGF-C
and VEFG-D possess the ability to bind to VEGFR-2, a recep-
tor associated with angiogenesis (Joukov et al., 1997; Stacker
et al., 1999; Lohela et al., 2009). Moreover, VEGF-C was shown
to promote angiogenesis in vivo and to promote angiogenesis, in
addition to lymphangiogenesis, in melanoma models (Cao et al.,
1998; Skobe et al., 2001b). VEGFR-3 is also associated with the
promotion of angiogenesis. In a study on mouse angiogenesis
models, the blockage of VEGFR-3 with monoclonal antibodies
was found to decrease sprouting, vascular density and endothe-
lial cell proliferation. Additionally a blockage of VEGFR-3 in
combination with the blockage of VEGFR-2 resulted in additive
inhibition of angiogenesis and tumor growth (Tammela et al.,
2008).
VEGF-A, a classical pro-angiogenic factor expressed by TAM,
was found to be involved also in lymphangiogenesis. Apart
from indirectly stimulating lymphangiogenesis by recruiting
macrophages (Cursiefen et al., 2004), VEGF-A has been shown to
induce proliferation and migration of VEGFR-2 expressing lym-
phatic endothelial cells (LEC) in vitro (Hong et al., 2004) and to
induce sentinel lymph node lymphangiogenesis in a skin cancer
model (Hirakawa et al., 2005). In a fibrosarcoma model, VEGF-
A displayed the ability to induce peritumoral lymphangiogenesis
as well as contribute to lymphatic metastasis (Bjorndahl et al.,
2005a). Anti-VEGF-A therapy proved to be an effective way to
reduce both blood and lymphatic vascular densities in a breast
cancer model. Moreover, it decreased the VEGFR-3 expression
levels in LEC and reduced the incidence of regional and distant
metastasis (Bjorndahl et al., 2005b; Whitehurst et al., 2007).
In addition to the expression of direct inducers of lymphan-
giogenesis, TAM regulate lymphangioegensis, also indirectly, by
the production of enzymes, such as MMP, plasmin and uroki-
nase plasminogen activator (uPA), that regulate matrix remod-
eling and growth factor activation (Allavena et al., 2008). Matrix
remodeling and growth factor activation are very important pro-
cesses, both in angiogenesis and lymphangiogenesis. MMP-2 and
MMP-9 have been shown to have a role in governing the for-
mation of lymphatic vessels. MMP-2 facilitates LEC migration
through collagen fibers, which is otherwise affected by physi-
cal matrix constraints. Inhibition or downregulation of MMP-2
and MMP-9 reduces lymphangiogenesis, the invasive ability and
tube-forming properties of LEC (Nakamura et al., 2004; Detry
et al., 2012) that supports the idea that MMP-2 and MMP-9-
mediated lymphangiogenesis contribute their ability to promote
several types of tumors. Along with MMP-1 and MMP-2, uPA
was shown to have a role in lymphatic progression of oral tongue
squamous cell carcinoma (Zhang et al., 2011a). Plasmin has been
reported to activate the lymphangiogenic growth factors VEGF-
C and VEGF-D. Proteolytic processing of these growth factors by
plasmin greatly enhanced their affinity to VEGFR-3 and binding
to both VEGFR-2 and VEGFR-3 (McColl et al., 2003).
Numerous other pro-lymphangiogenic factors have been iden-
tified in recent years. Among them are ADM, angiopoietin 1 and
2 (Ang-1, Ang-2), COX-2, endothelin-1, fibroblast growth factor-
2 (FGF-2), growth hormone, heparanase, hepatocyte growth
factor (HGF), insulin-like growth factors 1 and 2 (IGF-1, IFG-
1), platelet-derived growth factor-BB (PDGF-BB) and tumor
necrosis factor alpha (TNF-α) (Duong et al., 2012; Ran and
Montgomery, 2012). Although these factors have been linked to
lymphangiogenesis, the evidence that TAM are expressing them
during carcinogenesis as part of their lymphangiogenic activity
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is still insufficient. Future studies will shed light on the role of
TAM in the complex control of tumor lymphangiogenesis by the
production of cocktails of regulators of lymphangiogenesis.
THE ROLE OF TAM DENSITY IN TUMOR TISSUE AND ITS
ASSOCIATION WITH LYMPHANGIOGENESIS
The idea that TAM regulate tumor lymphangiogenesis is strongly
supported by a significant correlation between the density of
TAM and LVD in tumor tissues. In human cervical cancer,
VEGF-C expressing TAM were found to correlate with increased
LVD in peritumoral stroma. All TAM producing VEGF-C were
also expressing VEGF-D and VEGFR-3 and were distinguished
from other cells by CD68, CD14, CD23, HLA-DR, and CD45
(Schoppmann et al., 2002). In a mouse model of breast cancer,
Ito et al. demonstrated a clear correlation between the density
of LYVE-1+ lymphatic vessels, CD68+ macrophage infiltration,
and VEGF-C expression. By comparison of breast cancer cell lines
BJMC338 and BJMC3879 having low and high metastatic poten-
tial, respectively, more aggressive tumors were found to have an
increased infiltration of CD68+ macrophages, higher expression
of VEGF-C and a higher LVD (Ito et al., 2011).
In human breast cancer, higher numbers of TAM expressing
VEGF-C were associated with a higher LVD and lymph node
metastasis or lymph vessel invasion (LVI) (Ding et al., 2012).
Similar results were found in other types of tumors as well. A
study on ciliary body melanoma showed a significant correla-
tion between LYVE-1+ andD2-40+ intraocular lymphatic vessels,
higher CD68+ macrophage infiltration rate and an increased
mortality rate (Heindl et al., 2010). Another study on melanoma
revealed a correlation between CD68+ macrophages and D2-
40+ lymphatic vessel invasion, but showed no association with
clinical outcomes (Storr et al., 2012). In human skin squamous
cell carcinoma, increased LYVE-1+ LVD was found to be associ-
ated with increased VEGF-C secretion by CD68+ and/or CD163+
macrophages (Moussai et al., 2011). Similar results were obtained
by Werchau et al. in a study of Merkel cell carcinoma. Here,
VEGF-C secreting CD68+ and/or CD163+ macrophages were
also found to increase LYVE-1+ or D2-40+ LVD (Werchau et al.,
2012). Unfortunately, both of these studies failed to provide
a prognostic significance for these correlations. In a study of
lymphangiogenesis in gastric cancer, CD68+ TAM were shown
to be associated with a higher D2-40+ LVD and were closely
related to serosa invasion and lymph node metastasis (Wu et al.,
2012). In pancreatic cancer, VEGF-C expressing M2-polarized
macrophages had an association with increased LVD density and
incidence of tumor cells in regional lymph nodes (Kurahara et al.,
2013).
Positive correlations between the number of TAM, LVD
and tumor progression was also demonstrated for lung and
esophageal cancers (Ohta et al., 2002; Kurahara et al., 2011; Zhang
et al., 2011b). Not all studies were able to show a correlation
between TAM, LVD and tumor progression, and some expla-
nation to this phenomenon can be found in a recent review
(Ran and Montgomery, 2012). Moreover, our examination of the
TAM phenotype in pancreatic insulinoma and melanoma mouse
models demonstrated that LYVE-1 can be expressed not only
by lymphatic vessels, but also by TAM themselves (Schledzewski
et al., 2006). Subtraction of CD68+LYVE+ macrophages has to
be done for precise quantification of lymphatic vessels in tumors
without counting LYVE-1+macrophages. LYVE-1 is not the only
marker expressed by both TAM and the microvascular cells in
tumors. Stabilin-1 is also abundantly expressed on TAM and
non-continuous endothelium and probably on lymphatic ves-
sels (Kzhyshkowska et al., 2006b; Martens et al., 2006; Karikoski
et al., 2009; Kzhyshkowska, 2010). The available information
about the role of TAM in tumor lymphangiogenesis is summa-
rized in Table 1, and a solid body of data indicate that TAM are
able to support tumor lymphangiogenesis by direct and indirect
effects on EC using a broad spectrum of growth factors, cytokines
and enzymes overlapping with pro-angiogenic factors.
CHITINASE-LIKE PROTEINS AS NEW REGULATORS OF
TUMOR GROWTH AND VASCULARIZATION
Recently, a new potent inducer of angiogenesis, YKL40, has been
reported for several types of cancer (Shao et al., 2009; Faibish
et al., 2011; Francescone et al., 2011, 2013). YKL-40 belongs to the
family of Glyco_18 containing proteins that comprises chitinases
and chitinase-like proteins (CLPs) (Kzhyshkowska et al., 2006c,
2007). Mammalian CLPs include YKL-39, YKL-40, stabilin-1
interacting chitinase-like protein (SI-CLP) and YM1/YM2 (only
in rodents) that contain a Glyco_18 domain only; they lack criti-
cal amino acids within the catalytic site (Figure 2) and therefore
do not exhibit enzymatic activity (Kzhyshkowska et al., 2006c,
2007). Their biological activity is defined by specific interac-
tions mediated by the enzymatically silent Glyco_18 domain.
The Glyco_18 domain is characteristic for the evolutionary con-
served chitinases, which belong to the family of 18 glycosyl
hydrolases. Enzymatically active chitinases catalyze the hydroly-
sis of chitin, while their evolutionary conserved function in lower
life forms is to provide host defense against chitin-containing
organisms (Arakane and Muthukrishnan, 2010). However, at the
moment we have only limited information about the biological
functions of enzymatically silent CLPs that are induced during
inflammation and cancer. Major cell types that express CLPs are
macrophages and tumor cells. CLPs are secreted in the extracel-
lular space and therefore can mediate cellular crass-talk. CLPs
can also be found in circulation and can act both locally and
systemically.
YKL-40, also called human cartilage glycoprotein-39 (HCgp-
39), gp38k and Chitinase-3-like-1 (CHI3L1), is the best investi-
gated human chitinase-like protein regarding its association with
various disorders. Increased concentrations of YKL-40 in circu-
lation are associated with disorders characterized by different
types of inflammation and active tissue remodeling, including
asthma, arthritis, atherosclerosis and other cardiovascular disor-
ders (Wang et al., 2008; Kastrup, 2011; Harutyunyan et al., 2012;
Jensen et al., 2013; Konradsen et al., 2013). Circulating YKL-40
can be detected in human serum or plasma using RIA based
on polyclonal antibodies. Most intensively, circulating YKL-40
was investigated in tumor patients (Johansen et al., 2009; Allin
et al., 2012). Elevated levels of YKL-40 were found in the cir-
culation of patients with various solid tumors including glioma,
breast cancer, colorectal cancer, ovarian cancer, metastatic renal
and prostate cancer, and malignant melanoma. In breast cancer
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Table 1 | Role of TAM in tumor lymphangiogenesis and tumor progression.
Model TAM phenotype Action/correlation Method References
Cervical cancer CD68, CD14, CD23, HLA-DR,
and CD45
Express VEGF-C,VEGF-D, VEGFR-3
Increased LVD in peritumoral stroma
IHC, IF, Confocal
microscopy
Schoppmann et al.,
2002
Lung adenocarcinoma CD68, CD206 Increased LVD, increased lymph node
metastasis rate, poor prognosis
IHC, IF, Confocal
microscopy
Zhang et al., 2011b
Esophageal carcinoma CD68 Increased microvessel density IHC Ohta et al., 2002
Pancreatic cancer CD68, CD163, CD204 Increased LVD in cases with high
number of CD163/CD204 TAM
Increased lymph node metastasis rate
in cases with high number of CD163/
CD204 TAM
IHC Kurahara et al., 2011,
2013
Gastric cancer CD68 Higher LVD
Increased lymph node metastasis rate
IHC Wu et al., 2012
Merkel cell carcinoma CD68 and/or CD163 VEGF-C expression
Increased LVD
IHC, IF Werchau et al., 2012
Skin squamous cell carcinoma CD68 and/or CD163 VEGF-C expression
Increased LVD
IHC, IF Moussai et al., 2011
Melanoma CD68 Increased LVD IHC Storr et al., 2012
Ciliary body melanoma CD68 Increased LVD
Increased mortality rate
IHC Heindl et al., 2010
Mouse model of breast cancer CD68 Increased LVD and VEGF-C expression IHC Ito et al., 2011
FIGURE 2 | Mammalian chitinase-like proteins (CLP) belong to the
family of Glyc_18-containig proteins. (A) Schematic presentation of
mammalian Glyco_18 domain containing proteins. (B) Critical amino acid
in catalytic sites. The characteristic FDG sequence preceding the
catalytic motif is shown in the shadowed box. Catalytic amino acids are
shown in bold. Complete active catalytic motifs are underlined. This
research was originally published in Blood. Kzhyshkowska et al. (2006c)
© the American Society of Hematology.
patients, high levels of serum YKL-40 are associated with a poor
prognosis (Jensen et al., 2003; Johansen et al., 2003; Kim et al.,
2007; Yamac et al., 2008; Shao et al., 2011). In primary breast
tumors, YKL-40 protein expression was found in tumor cells
and in infiltrating inflammatory cells (Roslind et al., 2008). High
expression was associated with positive estrogen and progesterone
receptor status and high tumor differentiation. Serum levels of
YKL-40 are indicative of a poor prognosis and rapid metastatic
process. For example, increased plasma concentration of YKL-40
is related to poor prognosis and shorter survival of patients with
ovarian cancer, colorectal carcinoma, metastatic prostate carci-
noma and melanoma. A recent study demonstrated that YKL-40
expression in anal carcinoma is correlated with a poor outcome
and can predict lymph node metastases (Mistrangelo et al., 2013).
Differential levels of YKL-40 may reflect differences in the biol-
ogy of cancer cells themselves, as well as the activation of innate
immune responses in primary tumors, in particular, the activity
and functional polarization of TAM.
YKL-40 is also the best functionally investigated protein out of
all CLPs. Its stimulatory effect on tumor angiogenesis was demon-
strated in several studies. Porcine homolog of YKL-40, gp38k
(CHI3L1), specifically induces the migration of vascular smooth
muscle cells (VSMC), but not fibroblasts. Moreover, gp38k pro-
motes the attachment and spreading of VSMC (Nishikawa and
Millis, 2003). Elevated serum levels of YKL-40 are associated
with a worse prognosis among various advanced human cancers.
Recently YKL-40 was found to act as a strong pro-angiogenic
factor in cancer. It has been found that ectopic expression
of YKL-40 in MDA-MB-231 breast cancer cells and in HCT-
116 colon cancer cells led to larger tumor formation with an
extensive angiogenic phenotype than did control cancer cells in
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mice. Affinity-purified recombinant YKL-40 protein promoted
vascular endothelial cell angiogenesis in vitro, the effects of
which are similar to the activities observed using MDA-MB-
231 and HCT-116 cell-conditioned medium after transfection
with YKL-40. Blockade of YKL-40 using small interfering RNA
(siRNA) suppressed tumor angiogenesis in vitro and in vivo.
Immunohistochemical analysis of human breast cancer showed
a correlation between YKL-40 expression and blood vessel den-
sity (Shao et al., 2009). Furthermore, a potential receptor for
chitinase-like protein was identified for the first time in this
study. YKL-40 is a heparin-binding protein and syndecans are
a major source of cell surface heparin sulfate (HS). HS func-
tions as a key mediator connecting membrane receptors with
extracellular heparin-binding proteins, such as ECM protein vit-
ronectin and angiogenic factors (FGF, VEGF) (Lambaerts et al.,
2009). Shao et al. showed that YKL-40 induces a coordination of
membrane-bound receptor syndecan-1 and integrin alphavbeta3
and activates an intracellular signaling cascade, including focal
adhesion kinase and the MAP/Erk pathway (Shao et al., 2009).
YKL-40 also stimulates VEGF expression in U87 glioblastoma cell
line cells and synergistically with VEGF promote angiogenesis
(Francescone et al., 2011). YKL-40 is also able to enhance contact
of tumor and EC, to restrict vascular leakage and stabilize vascular
networks (Francescone et al., 2013).
Blocking of YKL-40 activity with monoclonal antibodies
demonstrated that this can be a promising therapeutic strategy for
advanced tumors (Faibish et al., 2011). Amousemonoclonal anti-
YKL-40 antibody (mAY) abolished YKL-40-induced activation of
VEGF receptor 2 (Flk-1/KDR) and MAP-mediated intracellular
signaling, and abrogated angiogenesis induced by YKL-40 con-
ditioned medium of the glioblastoma cell line U87 with elevated
levels of YKL-40 induced by γ-irradiation. Consequently, treat-
ment of xenografted tumor mice with mAY suppressed tumor
growth and angiogenesis (Faibish et al., 2011). More information
about the mode of action of YKL-40 in tumors and its prognostic
and therapeutic value can be found in the recent review of Shao
(2013).
YKL-39 was identified as an abundantly secreted protein in
primary culture of human articular chondrocytes (Halin et al.,
2009). YKL-39 is currently recognized as a biomarker for the acti-
vation of chondrocytes and osteoarthritis (OA) progression in
humans. YKL-39 might be an inducer of autoimmune processes
related to arthritis, while antibodies against YKL-39 were found
in patients with rheumatoid arthritis (RA) and OA (reviewed
in Kzhyshkowska et al., 2007). For a long time, it was believed
that macrophages do not secrete YKL-39. However, recently we
demonstrated that the key regulatory factor of tumor progression,
TGFß, strongly stimulates YKL-39 expression in macrophages
in vitro (Gratchev et al., 2008) suggesting that YKL39 might
be a biomarker for subpopulations of macrophages that under-
went programming by TGFß in the tumor microenvironment.
However expression of YKL39 on macrophages in vivo remains
to be examined experimentally.
SI-CLP was identified by us as stabilin-1- interacting
chitinase-like protein using yeast two-hybrid screening technol-
ogy (Kzhyshkowska et al., 2006c). In parallel with its sorting
receptor stabilin-1, expression of SI-CLP mRNA was strongly
upregulated in macrophages stimulated by Th2 cytokine IL-4 and
by dexamethasone. We developed a rat monoclonal antibody,
1C11, recognizing the N-terminal epitope of SI-CLP. This epitope
is located upstream of the conservative Glyco_18 domain and
has no similarity with sequences of other human Glyco_18 con-
taining proteins. Using the 1C11 antibody, we demonstrated that
the combination of IL-4 and dexamethasone increases SI-CLP
expression in macrophages. 1C11mAb recognized SI-CLP in the
cellular fraction of bronchoalveolar lavage specimens obtained
from patients with chronic inflammatory disorders of the respi-
ratory tract and in peripheral blood leukocytes (PBLs) from these
patients. SI-CLP is the only chitinase-like protein which is upreg-
ulated by glucocorticoids. However, the expression of SI-CLP in
tumor cells and TAM, and role of SI-CLP in cancer remain to be
investigated.
In summary, the identification of YKL-40 as a pro-angiogenic
factor in animal models and in vitro studies opens a new field of
investigation of the specific role of CLPs in regulation of tumor
growth and angiogenesis. The role of YKL-39 and SI-CLP in
tumor angiogenesis has not been reported up to date, however
their homology with YKL-40 makes these proteins attractive can-
didates for the analysis of their effects on tumor angiogenesis and
such studies are in progress in our laboratory. The ability ofmulti-
ple macrophage-derived pro-angiogenic factors to induce growth
of both lymphatic and blood vessels raises the possibility for the
involvement of YKL-40 and other CLPs proteins in the tumor
lymphangiogenesis. Further experimental efforts are required in
order to address the role of CLPs in lymphangiogenesis.
CONCLUSIONS AND PERSPECTIVES
There are no doubts today that TAM are critical controllers of
both tumor angiogenesis and lymphangiogenesis. They produce
soluble factors which either directly induce vessel formation or
enhance production of angiogenic factors by tumor cells. TAM-
mediated support of vessel growth is associated with increased
tumor growth and metastasis. Thus, targeting of TAM appears
to be a promising approach for tumor therapy and can be
achieved on both cellular and molecular levels. First, complete
systemic depletion of macrophages can be performed. However,
this approach raises significant concerns since prolonged absence
of these cells in organs and circulation may result in sensitiza-
tion to bacterial infections, and affect functionality of the whole
immune system.
Another possibility is to block the recruitment of specific
pro-angiogenic TAM populations into tumor site. Analysis of
published data suggests that the disruption of CXCL12-CXCR4,
ANG2-TIE2, and VEGF-VEGFR axes can prevent infiltration of
tumors by angiogenic TAM populations. This approach appears
to be promising to inhibit the repopulation of hypoxic tumor
areas by TAM after therapeutic interventions. Finally, pro-
angiogenic activity of TAM is based on, but not limited by,
the release of common angiogenic factors such as VEGF-A and
MMP9. Recent reports reveal novel TAM-derived angiogenic fac-
tors including ADM, Sema4D, and YKL-40 in specific tumor
types. Thus, it is possible that a tumor-specific microenviron-
ment induces the expression of distinct pro-angiogenic programs
in TAM depending on tumor type and affected organ. Therefore,
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the identification of novel TAM-derived angiogenic factors and
the validation of their targeting in specific types of cancer is
urgently needed. The limitation of this method is related to the
fact that TAM release a cocktail of pro-angiogenic factors, and tar-
geting of single factor can be insufficient for suppression of tumor
vascularization. Macrophages are not terminally differentiated
and show high level of plasticity that makes TAM attractive tar-
gets for therapeutic immunomodulation (Stout and Suttles, 2004;
Gratchev et al., 2006; Stout et al., 2009). Manipulating TAM phe-
notype and their re-polarization from pro-angiogenic M2 into
anti-angiogenic M1 cells is an advanced strategy to solve this
problem. HIF-1, COX-2, and NF-kB can be considered as promis-
ing target molecules for macrophages re-polarization. Moreover,
correction of macrophage polarization in combination with tar-
geting of single soluble factors, despite being sophisticated and
requiring solid experimental investment, opens new horizons for
an efficient and personalized cancer therapy.
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